Elicio Therapeutics ELTX Cash Flow Statement (2020-2026)

NASDAQ ELTX
$2.11 -0.07 (-3.23%)
As of: Sep 10, 2026 · 3:59 PM EDT
Reported Financials

Elicio Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Elicio Therapeutics reported cash from operations of -$8.16M and free cash flow of -$8.00M for the quarter ended Jun 2026, up 8.8% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M-10.70M
Share-based CompensationStock Comp.
2.18M2.02M0.03M0.24M0.11M0.20M0.22M0.28M0.34M0.34M0.32M0.35M0.31M0.46M0.52M0.71M0.70M0.77M0.87M0.94M
Gains from Investment SecuritiesGains Investment
-0.13M-0.27M-0.04M0.02M-0.01M-0.01M1.28M-3.62M5.62M0.61M0.51M0.86M1.81M-1.26M0.98M-2.48M
Cash from OperationsCash from Ops.
-15.20M-14.36M-15.65M6.14M-5.39M-7.28M-8.14M-9.47M-5.18M-9.89M-12.12M-8.93M-7.27M-8.74M-10.12M-8.95M-11.09M-6.80M-11.64M-8.16M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.19M0.19M0.20M0.09M0.19M0.19M0.40M0.18M0.21M0.21M0.21M0.03M0.22M0.23M0.23M0.40M0.24M0.24M0.10M
Amortization of Deferred ChargesAmort. Deferred Charges
Change in Working Capital
Change in Account PayablesChange Payables
-1.66M-2.94M-1.32M3.08M-0.35M-0.28M1.39M-1.46M0.14M-0.04M-3.26M-0.05M0.93M-0.95M3.00M-0.17M-3.54M0.35M-0.46M0.63M
Change in Accured ExpensesChange Accured Exp.
0.84M-2.17M2.02M-1.91M-0.18M-0.23M-0.38M0.12M2.16M0.31M-0.43M2.04M-0.51M3.56M-2.65M-0.66M0.11M1.21M-0.60M1.47M
Other Working Capital ChangesOther WC Changes
-1.46M-25.14M-1.65M1.65M2.15M-0.72M-0.51M-0.93M1.66M-0.97M-0.07M-0.28M0.96M-0.14M-0.49M-0.68M
Investing Activities
Capital ExpendituresCapex
0.06M0.04M-0.03M0.59M0.10M-0.20M0.22M0.04M-0.16M-1.04M-1.03M0.17M0.23M-0.17M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.03M0.00M
Cash from Investing ActivitiesCash from Investing
-0.06M-0.04M-0.56M-0.10M-0.02M0.03M-0.04M0.00M-0.04M-0.04M-0.02M
Financing Activities
Other financing activitiesOther financing
0.01M0.11M0.08M-0.06M0.07M0.04M0.03M0.06M5.96M16.92M-16.90M0.34M0.95M0.10M0.02M
Cash from Financing ActivitiesCash from Financing
0.70M0.40M-0.01M1.26M8.78M11.18M10.04M21.51M0.06M7.00M11.02M0.32M30.75M0.23M10.33M11.93M9.57M4.86M8.03M16.51M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
-3.07M1.17M8.84M11.11M7.00M5.06M0.30M0.05M-0.86M0.83M2.02M
Additional items
Exchange Rate EffectFX Effect
-0.02M0.01M-0.09M0.09M0.08M-0.08M0.00M-0.04M0.04M0.03M0.03M0.07M0.04M-0.10M0.01M-0.00M
Change in Cash
-14.58M-13.98M-15.75M6.92M3.39M3.81M1.88M12.06M-5.17M-2.89M-1.09M-8.70M23.52M-8.54M0.24M3.06M-1.48M-2.05M-3.61M8.34M
Free Cash FlowFCF
-15.26M-14.40M-15.62M5.55M-5.39M-7.37M-7.94M-9.69M-5.23M-9.89M-11.96M-7.89M-6.24M-8.74M-10.12M-8.95M-11.26M-6.80M-11.87M-8.00M
Net Cash FlowNCF
-14.56M-13.99M-15.67M6.84M3.39M3.81M1.88M12.07M-5.17M-2.89M-1.09M-8.65M23.48M-8.56M0.21M2.98M-1.51M-1.95M-3.62M8.35M